Floatz logo

Abt-301

Tumors

Mateon TherapeuticsPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Tumors cohort.

Asset / SponsorPhaseRating
Iniparib
Sanofi
Phase 3BB
Rasburicase
Sanofi
Phase 4BB
PEGFILGRASTIM
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2BB
Vorinostat
Memorial Sloan Kettering Cancer Center
Phase 1/2B
Fosbretabulin
Mateon Therapeutics
Phase 2B

View all 42 →

Same molecule, other indications

Abt-301 is also rated in:

Metastatic Colorectal CancerDormant
B
Indicative ·
63 / 100
View asset →
Metastatic MelanomaDormant
CCC
Indicative ·
54 / 100
View asset →
Colorectal NeoplasmsDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →